Thrombotic thrombocytopenic purpura associated with clopidogrel

Article Abstract:

The anticoagulant drug clopidogrel may cause thrombotic thrombocytopenic purpura (TTP). TTP is a life-threatening condition characterized by abnormal blood clot formation and other abnormalities. Clopidogrel was developed partly to replace the anticoagulant drug ticlopidine, which can also cause TTP. During the development and testing of clopidogrel, no cases of TTP were observed in 20,000 patients who took the drug. But doctors now report 11 patients who developed TTP after taking the drug. Ten developed TTP within two weeks of taking the drug. One patient died from the condition despite treatment.

Complications and side effects, Clopidogrel

---

The research on Adverse Drug Events and Reports (RADAR) project

Article Abstract:

A study was conducted to evaluate the structure, operations, and preliminary findings from the Research on Adverse Drug events And Reports (RADAR) project and related dissemination efforts by pharmaceutical suppliers and the US Food and Drug Administration. The result showed that a new, clinically based, hypothesis-driven approach to postmarketing surveillance may supplement existing regulatory surveillance and improve patients safety.

United States, Science & research, Management dynamics, Research, Management, Drugs, Reports, Company business management, United States. Food and Drug Administration, Adverse drug reactions

---

Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura

Article Abstract:

Antibodies that inhibit von Willebrand factor-cleaving protease may be a cause of thrombotic thrombocytopenic purpura. Thrombotic thrombocytopenic purpura is a bleeding disorder caused by abnormal blood clotting. Researchers tested blood samples from 37 people with thrombotic thrombocytopenic purpura for antibodies against von Willebrand factor-cleaving protease. This enzyme breaks down clumps of von Willebrand factor. All patients had low levels of the protease, and in 67%, an IgG antibody was inhibiting the enzyme.

Health aspects, Proteases, Enzyme inhibitors

Similar abstracts:

• Abstracts: Activation of the transcription factor NF-kappaB in the rat air pouch model of inflammation. Oxygen free radicals, inflammation, and synovitis: the current status
• Abstracts: The causes and risk of stroke in patients with asymptomatic internal-carotid-artery stenosis. Prognosis after transient monocular blindness associated with carotid-artery stenosis
• Abstracts: Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.